F-1/A: INLIF Limited Files for IPO, Aiming to List on Nasdaq

INLIF Limited, a Cayman Islands-based holding company with primary operations in China, is pursuing an initial public offering to list its Ordinary Shares on the Nasdaq Capital Market.

Summary

• INLIF Limited, a Cayman Islands holding company, has filed for an IPO to list its Ordinary Shares on the Nasdaq Capital Market.
• The company's primary operations are conducted through its Operating Entity in China, which specializes in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms.
• The IPO aims to offer 2,000,000 Ordinary Shares with an expected price range of $4 to $6 per share.
• Following the offering, key officers, directors, and major shareholders will collectively control approximately 86.2% of the Ordinary Shares.
• The company intends to use the IPO proceeds for expanding its production capabilities, establishing local marketing offices, and investing in R&D.
• The company faces legal and operational risks associated with its business operations in China, including regulatory uncertainties and potential government intervention.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company shows strong revenue growth and has positive plans for the future, it also faces significant regulatory and competitive risks, particularly related to its operations in China. The potential for government intervention and delisting under the HFCA Act are major concerns.

Positives

• The company has a strong research and development capability.
• The company has a comprehensive quality control system.
• The company has an experienced management team.
• The company has a broad range of customer base.
• The company's revenue increased by $5,958,565, or 89.57%, from 2022 to 2023.
• The company's revenue increased by $1,913,062, or 39.67%, for the six months ended June 30, 2024, compared to the six months ended June 30, 2023.

Negatives

• The company faces legal and operational risks associated with its business operations in China.
• The company is subject to regulatory uncertainties and potential government intervention in China.
• The company's Ordinary Shares may be delisted under the Holding Foreign Companies Accountable Act (HFCA Act).
• The company does not intend to pay dividends in the foreseeable future.
• The company operates in a highly competitive market.
• The company relies on a limited number of suppliers for raw materials.

Risks

• Chinese regulatory authorities could disallow the company's holding company structure.
• The impact of the Cyberspace Administration of China's (CAC) increasing oversight over data security remains highly uncertain.
• The company may be influenced by changes in the political and economic policies of the PRC government.
• Uncertainties with respect to the enforcement of laws, and changes in laws and regulations in China with little advance notice, could materially and adversely affect the company.
• The PRC government exerts substantial influence over the manner in which the PRC subsidiaries conduct their business activities.
• The Ordinary Shares may be delisted under the HFCA Act.
• The company may rely on dividends and other distributions on equity paid by its PRC subsidiaries to fund any cash and financing requirements it may have, and any limitation on the ability of its PRC subsidiaries to make payments to it could have a material and adverse effect on its ability to conduct its business.
• The company may be deemed to be a PRC resident enterprise under the Enterprise Income Tax Law, and be subject to the PRC taxation on its worldwide income, which may significantly increase its income tax expenses and materially decrease its profitability.
• The company faces uncertainties in the PRC with respect to indirect transfer of equity interests in its PRC subsidiaries.
• Conversion of RMB to and from other currency may be subject to governmental control in China.
• You may experience hardships in effecting service of legal process, enforcing foreign judgments, or bringing actions in China against us or our management named in this prospectus based on foreign laws.
• It may be difficult for overseas regulators to conduct investigations or collect evidence within the PRC.
• The Operating Entity operates in a highly-competitive market and its failure to compete effectively could adversely affect both its and our business, financial condition, and results of operations.
• The Operating Entitys research and development, acquisition and licensing efforts may fail to generate new products.
• Manufacturing problems may cause product launch delays, inventory shortages, recalls or unanticipated costs.
• The Operating Entity may fail to detect or cure defects of its products.
• If the Operating Entity fails to successfully develop and commercialize new industrial manipulator arms in a timely manner, the operating results may be materially adversely affected.
• Our historical growth rates and performance may not be sustainable or indicative of our future growth and financial results. We cannot guarantee that we will be able to maintain the growth rate we have experienced to date.
• The Operating Entitys business requires a number of permits and licenses. We cannot assure you that the Operating Entity can maintain all required licenses, permits and certifications to carry on its business at all times.
• If we cannot retain, attract, and motivate key personnel, we may be unable to effectively implement our business plan.
• The Operating Entity may be accused of infringing, misappropriating or otherwise violating the intellectual property rights of third parties.
• Damage to our brand image could have a material adverse effect on our growth strategy and our business, financial condition, results of operations and prospects.
• The Operating Entity may not successfully acquire and integrate other businesses, license rights to technologies or products, form and manage alliances or divest businesses.
• There has been no public market for our Ordinary Shares prior to this offering, and you may not be able to resell our Ordinary Shares at or above the price you pay for them, or at all.
• The initial public offering price for our Ordinary Shares may not be indicative of prices that will prevail in the trading market and such market prices may be volatile.
• You will experience immediate and substantial dilution in the net tangible book value of Ordinary Shares purchased.
• If we fail to implement and maintain an effective system of internal controls or fail to remediate the material weaknesses in our internal control over financial reporting that have been identified, we may fail to meet our reporting obligations or be unable to accurately report our results of operations or prevent fraud, and investor confidence and the market price of our Ordinary Shares may be materially and adversely affected.
• We will incur substantial increased costs as a result of being a public company.
• Substantial future sales of our Ordinary Shares or the anticipation of future sales of our Ordinary Shares in the public market could cause the price of our Ordinary Shares to decline.
• We do not intend to pay dividends in the foreseeable future.
• The market price of our Ordinary Shares may be volatile or may decline regardless of our operating performance, and you may not be able to resell your shares at or above the initial public offering price.
• The price of our Ordinary Shares could be subject to rapid and substantial volatility. Such volatility, including any stock run-ups, may be unrelated to our actual or expected operating performance and financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our Ordinary Shares.
• Our management has broad discretion to determine how to use the funds raised in the offering and may use them in ways that may not enhance our results of operations or the price of our Ordinary Shares.
• If we cease to qualify as a foreign private issuer, we would be required to comply fully with the reporting requirements of the Exchange Act applicable to U.S. domestic issuers, and we would incur significant additional legal, accounting and other expenses that we would not incur as a foreign private issuer.
• Because we are a foreign private issuer and are exempt from certain Nasdaq corporate governance standards applicable to U.S. issuers, you will have less protection than you would have if we were a domestic issuer.
• If we cannot continue to satisfy the listing requirements and other rules of the Nasdaq Capital Market, our securities may be delisted, which could negatively impact the price of our securities and your ability to sell them.

Future Outlook

The company intends to grow its business by enhancing production capacity, increasing R&D investment, and expanding its sales network.

Industry Context

The industrial manipulator arms market in China is highly competitive and rapidly evolving, with many new companies joining the competition in recent years and few leading companies.

Comparison to Industry Standards

• The top 10 manufacturers accounted for approximately 28.0% of the market share in Chinas manipulator arm market in 2022.
• In 2022, Ewatt ranked 10th among all the market participants, with a market share of approximately 1.4%.
• In terms of revenue generated from the injection molding industry, the top 10 China manipulator arm manufacturers accounted for approximately 29.6% of the market share in China manipulator arm market in 2022.
• In 2022, Ewatt ranked 8th among all the market participants, with a market share of approximately 1.8%.

Related Party Transactions

• For the six months ended June 30, 2024, the related parties provided working capital to support the Operating Entitys operations when needed.
• For the fiscal year ended December 31, 2023, the related parties provided working capital to support the Operating Entitys operations when needed.
• For the fiscal year ended December 31, 2022, the related parties provided working capital to support the Operating Entitys operations when needed.
• For the six months ended June 30, 2024 and the years ended December 31, 2023, 2022, and 2021, the Company generated revenue from related parties in the amount of $3,651, $13,985, $178,311, and $9,027, respectively.

Stakeholder Impact

• Shareholders face risks related to regulatory uncertainties, potential government intervention, and the possibility of delisting under the HFCA Act.
• Employees may benefit from the company's expansion plans and increased R&D investment.
• Customers may benefit from the company's plans to enhance production capacity and expand its sales network.
• Suppliers may benefit from the company's increased production capacity.

Next Steps

• The company needs to obtain final approval from Nasdaq for its listing application.
• The company plans to construct a 5G digital intelligent equipment production base.
• The company plans to establish 24 local marketing and service offices across the PRC.
• The company plans to construct an industrial robot and automation application technology research and development center.

Key Dates

Keywords

IPO, Nasdaq, Ordinary Shares, manipulator arms, China, INLIF Limited, financials, robotics, manufacturing, investment